omeprazole + amoxicillin + bismuth subcitrate + clarithromycin

This drug entry refers to a specific quadruple therapy regimen evaluated by the **Tehran University of Medical Sciences** for the eradication of *Helicobacter pylori* infection. The regimen typically consists of **omeprazole** (a proton pump inhibitor), **amoxicillin** (a penicillin-type antibiotic), **bismuth subcitrate** (a cytoprotective and antimicrobial agent), and either **clarithromycin** or **azithromycin** (macrolide antibiotics). In clinical trials, this combination was used to investigate whether the eradication of *H. pylori* could improve liver function tests and metabolic markers in patients with Non-alcoholic Fatty Liver Disease (NAFLD). Omeprazole functions by inhibiting the gastric H+/K+-ATPase enzyme, thereby reducing acid secretion and creating a more favorable environment for the antibiotics to act against the bacteria. Amoxicillin and clarithromycin/azithromycin work by disrupting bacterial cell wall synthesis and protein synthesis, respectively, while bismuth subcitrate exerts direct toxic effects on the bacteria and prevents their adhesion to the gastric mucosa.

Other names

H. pylori eradication regimenQuadruple therapyomeprazole + amoxicillin + bismuth subcitrate + azithromycin